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Abstract
Background—Clinician-rated measures of functioning are often used as primary endpoints in 
clinical trials and other behavioral research in Huntington disease. As study costs for clinician-
rated assessments are not always feasible, there is a question of whether patient self-report of 
commonly used clinician-rated measures may serve as acceptable alternatives in low risk 
behavioral trials.
Aim—The purpose of this paper was to determine the level of agreement between self-report and 
clinician ratings of commonly used functional assessment measures in Huntington disease.
Design—486 participants with premanifest or manifest Huntington disease were examined. Total 
Functional Capacity, Functional Assessment, and Independence Scale assessments from the 
Unified Huntington Disease Rating scale were completed by clinicians; a self-report version was 
also completed by individuals with Huntington disease. Cronbach’s alpha was used to examine 
internal consistency, one-way analysis of variance was used to examine group differences, and 
paired t-tests, kappa agreement coefficients, and intra-class correlations were calculated to 
determine agreement between raters.
Results—Internal consistency for self-reported ratings of functional capacity and ability were 
good. There were significant differences between those with premanifest, early-, and late-stage 
disease; those with later-stage disease reported less ability and independence than the other 
clinical groups. Although self-report ratings were not a perfect match with associated clinician-
rated measures, differences were small. Cutoffs for achieving specified levels of agreement are 
provided.
Conclusions—Depending on the acceptable margin of error in a study, self-reported 
administration of these functional assessments may be appropriate when clinician-related 
assessments are not feasible.
Carlozzi et al. Page 2
J Neurol. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Huntington disease; functioning; clinician-ratings; self-report ratings
Introduction
Huntington disease (HD) is an autosomal dominant inherited, progressive neurodegenerative 
disorder that causes profound cognitive, behavioral, and motor decline.[1, 2] The disease 
often manifests near age 40 and leads to death in 15–20 years.[1, 3, 4] Patients lose function 
in many areas, including occupational, social, financial, and activities of daily living.[5–7] 
Slowing functional loss is a major unmet need, and a prime goal of HD clinical trials.[8, 9] 
These trials require functional rating scales that, in some cases, may act as a primary 
endpoint.[5, 10]
The Unified Huntington’s Disease Rating Scale (UHDRS) is the most widely used 
assessment in clinical HD research.[11] The UHDRS includes clinician-rated assessments of 
functioning, motor symptoms, and cognition. With regard to the UHDRS functional 
assessments it includes: the Total Functional Capacity (TFC), the Functional Assessment 
(FA) Scale, and the Independence Scale.[12, 13] The TFC in particular is a frequently used 
as a primary outcome measure. e.g., [14–16] The entire UHDRS, including these scales, was 
designed and validated as a clinician-rated instrument.[11] The clinician completes the 
scales after focused interviews with the affect individual and/or a close informant.
Some behavioral and observation research trials in HD would substantially benefit if these 
scales could be accurately completed by patient self-report. Patients could then complete 
their own functional ratings electronically from home, for at least some time points, 
reducing the participant burden for studies that require frequent administrations of functional 
scales.[17] This could potentially decrease study costs and enhance recruitment and 
retention.[17, 18] Furthermore, patient-reported outcome measures, particularly as they 
pertain to health-related quality of life (HRQOL; the effect of a disease on one’s physical, 
cognitive, emotional, or social well-being [19, 20]) are becoming increasingly important as 
measures of efficacy for new treatments.[21, 22]
On the other hand, relying on patient self-report has potential disadvantages. One key 
question is whether self-ratings would be similar to (and therefore a reasonable substitute 
for) a trained clinician’s ratings using these functional rating scales. Cognitive dysfunction 
occurs even in premanifest HD (before motor symptoms manifest),[5, 23–26] and patient-
reported and caregiver-reported functional ratings may diverge in the early stages of disease, 
possibly related to subtle loss of awareness on the patient’s part.[27–32] These discrepancies 
might increase in late-stage HD, when dementia could interfere with a subject’s insight and 
item comprehension, or lead to perseverative responses. Another potential source of error is 
misunderstanding of a question’s intent. Most notably, many items in the UHDRS are 
intended to gauge the capacity to perform function X or Y, regardless of whether the subject 
actually performs X or Y with any regularity. This potential source of confusion could be 
mitigated with a trained clinician guiding the rating.
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The broader literature comparing self-report to clinical interview data is extremely variable. 
For example, while there is often consensus between self-reported and clinician interview 
for clinical diagnoses,[33–42] consensus reporting between the patient and clinician for 
specific symptoms and overall functioning can be highly variable [43–47]. Furthermore, the 
accuracy of retrospective self-reported symptoms may suffer from recall bias or memory 
decay[48, 49], and may be subject to exaggeration, especially in cases where litigation or 
compensation is involved [39–42]. Several different factors may account for this variability 
including the objectivity/subjectivity of the symptom that is the subject of the report, social 
desirability, time length for recall, the age and education of the informant, and the level of 
self-awareness of the rater. More work is needed to understand how patient self-report in HD 
relates to clinician ratings.
The primary aim of this analysis was to compare clinician-reported and patient-reported 
ratings of UHDRS functional measures. We hypothesized that for premanifest and early HD 
subjects, self-report would correlate well with clinician-report, but that increased 
discrepancy may occur in later stage HD. In addition, we examined the reliability of 
individual items (and groups) across different raters and compared the internal consistency 
of clinician and self-reported measures to determine if one measure was more stable than the 
other. We hypothesized that clinician-ratings would have greater stability than self-report 
measures. Finally, we examined the ability for both the clinician-ratings and self-report 
ratings to differentiate between those with premanifest versus manifest disease (i.e., known 
groups validity). Since those with manifest disease have greater functional deficits than 
those with premanifest disease [50], this would provide evidence of validity.
Methods
Participants
Participants with either premanifest (gene-positive status for the HD CAG expansion and no 
clinical diagnosis), or manifest HD were invited to participate in a study about HRQOL 
(characterization details provided below). This report focuses on a subset of participants that 
were examined as part of a larger study; detailed data about the full sample are reported 
elsewhere.[51] Briefly, participants must have been ≥18 years of age, able to read and 
understand English, and able to provide informed consent. This convenience sample 
included recruitment efforts through local HD treatment centers (at the University of 
Michigan, University of Iowa, University of California-Los Angeles, Indiana University, 
Johns Hopkins University, Rutgers University, Struthers Parkinson’s Center, and Washington 
University in St. Louis), the HD Roster, existing online medical record data capture systems,
[52] and community outreach. In addition, a portion of this sample was recruited in 
conjunction with the Predict-HD research study.[53] All study activities were conducted 
with the approval of local Institutional Review Boards and have therefore been performed in 
accordance with the ethical standards in the 1964 Declaration of Helsinki. Consent from 
participants was also obtained before subject participation began.
Carlozzi et al. Page 4
J Neurol. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Characterization of Huntington Disease (HD)
The Total Motor Scale and the Total Functional Capacity score from the Unified 
Huntington’s Disease Rating Scale (UHDRS)[11] were used to classify HD participants in 
this study. The 15-item clinician administered TMS evaluates multiple aspects of motor 
functioning (scores range from 0–124 with higher scores indicating more motor difficulties). 
The final item of this scale requires the clinician to indicate a confidence rating for whether 
or not the participant has unequivocal signs of HD (the rating scale ranges from 0 = No 
abnormalities to 4 = ≥99% confidence). In order to be classified as having premanifest HD, 
participants were required to have a positive gene test for the HD CAG expansion (CAG > 
35) and a clinician confidence rating of ≤ 4 on the last item of the TMS. In order to be 
classified as manifest HD, participants were required to have a clinician-based rating of 4 on 
the last item of the TMS. Staging for manifest participants was determined based on TFC 
scores (which includes five multiple-choice clinician-rated items addressing impairment or 
assistance required in occupation, finances, domestic chores, ADLs, and level of care). 
Scores range from 0–13 with higher scores indicating better functioning; early-HD (stages I-
II) had TFC scores between 7 and 13 and late-HD (stages III-IV) had TFC scores between 0 
and 6.
Measures
Demographics—Demographic information was collected using an online data capture 
system (Assessment CenterSM). Demographic data included age, gender, marital status, race, 
and ethnicity.
Medical Record Confirmation—Medical record data were retrieved to confirm HD 
diagnosis, date of HD diagnosis, and gene test results (including CAG repeat length). For 
manifest participants, the date of HD diagnosis was used to determine how many years had 
passed from diagnosis to the time of their study visit. For premanifest participants, the CAG 
repeat length and age at the time of their study visit were used to calculate their CAP score 
[54], which categorizes participants as either Low, Intermediate, and High risk of developing 
motor symptoms within the next five years.
The Unified Huntington’s Disease Rating Scale (UHDRS). [11]—The UHDRS is a 
standardized rating scale that assesses mobility, cognition, functionality, and independence.
[11] We examined three measures: Total Functional Capacity (TFC), the Functional 
Assessment (FA) Scale, and the Independence Scale. Two different administrations of these 
assessments were completed; the first was clinician-rated, and the second was patient self-
reported (see appendix for self-report versions of these assessments). The TFC includes five 
multiple-choice questions addressing impairment or assistance required in occupation, 
finances, domestic chores, ADLs, and level of care. Both clinician-rated and self-report TFC 
scores range from 0–13 with higher scores indicating better functioning. [11] The Functional 
Assessment Scale includes 25 yes/no questions pertaining to a participant’s ability to 
perform common tasks related to occupation, finances, activities of daily living (ADL), 
domestic chores, and level of care. Scores range from 0–25 for the clinician-rated and self-
report version of this measure, with higher scores indicating higher functioning. [11] The 
clinician-rated Independence Scale is rated from 1 to 100 in intervals of five, with higher 
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scores indicating higher functioning and lower scores indicating worse functioning.[11] The 
self-report Independence scale differs slightly, in that participants rate themselves on a scale 
of 0 to 10, without an option to select increments of 0.5. For the purposes of this analysis, 
the clinician-rated Independence scale was transformed by dividing the clinician score 
(ranging from 0 – 100) by 10 to match the scale of the self-report measure (0–10).
Statistical Analysis
Statistical analyses were performed with SAS 9.4 and SPSS Version 22.0.[55, 56] 
Descriptive statistics were analyzed separately for both the clinician rating and self-reported 
scores.
Reliability—Cronbach’s alpha coefficients were calculated to determine internal 
consistency of the UHDRS TFC and Functional Assessment for the clinician-rated and 
participant self-report. A critical cutoff of 0.70 was considered minimal acceptable 
reliability.[57] We used a dependent alpha (Feldt) t-test[58] to compare clinician and self-
report measures of the same test. The Independence Scale is comprised of a single item; 
therefore, internal consistency cannot be calculated.
Known Groups Validity—Known groups validity was assessed using a one-way ANOVA 
to determine whether the clinician and self-reported FA and Independence Scales could 
differentiate among the three HD groups. We hypothesized that premanifest participants 
would report higher levels of independence and functioning than the early-stage HD group, 
and that the early-stage HD group should report more independence and better functioning 
than the late-stage HD group.[50] Bonferonni (Dunn) t-tests were used to examine mean 
differences among the three groups.[59] Known groups validity was not assessed for TFC 
scores, since TFC scores are required to determine the HD staging groups.
Measurement Agreement between Clinician-Rated and Self-Report Scores—
The clinician-rated and self-report scores were compared using a paired t-test to determine 
the statistical significance of the mean difference in total TFC, FA, and Independence Scale 
scores. Next, individual TFC and FA items were compared between the clinician-rated and 
participant self-report rating using Cohen’s kappa coefficient.[60] A kappa score between 
0.81 and 1 was considered excellent agreement, 0.61–0.80 was considered substantial (very 
good) agreement, 0.41–0.60 was moderate agreement, 0.21–0.40 was deemed fair 
agreement, and lower than 0.20 indicated no agreement.[60, 61] A kappa coefficient for the 
Independence Scale could not be calculated because the clinician and the participant-rated 
scales differed (i.e., the clinician was allowed to choose intervals of 5). Intra-class 
correlation coefficients (ICCs) were calculated to analyze the group level reliability of the 
clinician rated items and the self-reported items. Overall agreement was measured by finding 
the percent of participants whose self-reported scores and clinician rated assessment scores 
were an exact match. Then, agreement between clinician-rated and self-reported Functional 
Assessment scores and TFC scores was examined at ascending discrepancy allowances to 
assess how much discrepancy would allow for different levels (75%, 90%, 95%, and 100%) 
of agreement.
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Results
Descriptive Data
We examined four hundred and eighty-six individuals with either premanifest (n=195) or 
manifest HD (early stage n=190 or late stage n=101). Groups did not differ on gender (X2 2 
= 4.0, p=. 1341). As expected, age significantly differed across groups (F[2, 483] = 45.3, 
p<0001); the average age of the premanifest group (M = 42.9; SD = 12.2) was nine years 
younger than the early group (M = 52.0; SD = 12.3) and thirteen years younger than the late 
stage group (M = 55.5; SD = 11.6). This is understandable given the progressive nature of 
the disease and the usual age of onset. Race (Fisher’s Exact p=.0053) and ethnicity (Fisher’s 
Exact p=. 0002) also differed across groups; the late-stage group had a higher proportion of 
African Americans than the other two groups, the late-stage group included a higher 
proportion of non-Hispanic participants than the other two groups and the premanifest group 
had a larger proportion of individuals whose ethnicity was not provided relative to the 
manifest groups. A description of the sample can be found in Table 1. The average score for 
the clinician rating of TFC was 9.54 (SD=3.68). This significantly differed (t[469]=6.10; 
p<0001) from the self-report ratings of the same measure (M=9.22; SD=3.97). For 
Functional Assessment, the clinician rating (M=19.02; SD=6.30) did not significantly differ 
from the self-report ratings (M=20.90; SD=5.57; t[302]=1.01; p=3141). Finally, clinician 
ratings on the Independence Scale (M=8.55; SD=1.61) were significantly lower 
(t[481]=6.24; p<0001) than self-reported scores (M=8.84; SD=1.58).
Reliability
Internal consistency data is provided in Table 2. Internal consistency for the clinician-rated 
TFC was good (Cronbach’s α = 0.89) and FA was excellent (Cronbach’s α = 0.95). 
Similarly, internal consistency was good for the self-reported TFC (Cronbach’s α = 0.86) 
and excellent for the FA (Cronbach’s α = 0.95). The internal consistency for the self-
reported TFC (Cronbach’s α = 0.86) was significantly lower than the clinician-rated TFC 
(t[468]=4.75; p<0001). Similarly, the self-report administration of the FA (Cronbach’s α = 
0.94) was also significantly lower than the clinician assessment (t[301]=2.16; p=.03), though 
numerically and clinically this difference is small.
Known Groups Validity
For the FA and the Independence Scale, both the clinician-rated measure and self-report 
measure were differentiated among the HD groups (Table 3). All findings were in the 
hypothesized direction (i.e., premanifest participants reported higher levels of independence 
and functioning than the early-stage HD group, and the early-stage HD group reported more 
independence and functioning than the late-stage HD group).
Measurement Agreement between Clinician-Rated and Self-Report Scores
The clinician-rated TFC significantly differed from self-report TFC (t[469]=6.10; p<.0001; 
Table 2). These significant differences were seen for both the premanifest (t[189]=4.31; p<.
0001) and early (t[180]=5.87; p<.0001) groups; in both cases clinicians rated participants as 
higher functioning than the participants themselves did. However, TFC scores did not 
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significantly differ in the late-stage group (t[98]=0; p=1). At the individual level, there was 
21.5% agreement between clinician-rated and self-reported scores. To achieve 75%, 90%, 
95%, and 100% agreement, clinician-rated and participant self-report scores had to be within 
2, 4, 5, and 7 points of each other, respectively (Table 4). Although the kappa was .14 
(indicating no inter-rater reliability) and agreement for the individual items was minimal to 
weak (kappa scores ranged from 0.17 to 0.58), the intra-class correlations for the total score 
was good (ICC = 0.88; 95% CI: 0.85, 0.90; see Table 5).
For the FA scale, clinician-ratings did not differ from the self-report scores for the overall 
sample (t[303]=1.01; p=.3141; Table 2). FA ratings significantly differed among the early-
stage participants (t[166]= 3.75; p=.0002), but not for the premanifest (t[44]= 1.59; p=.12) 
or late-stage participants (t[90]= −1.62; p=.11; Table 3). For the FA total score, there was 
29.9% exact agreement between the clinician and subjects, and a 75% agreement within a 2-
point window. To achieve 75%, 90%, 95%, and 100% agreement, FA scores needed to be 
within 2, 5, 7, and 13 points, respectively (Table 4). Although the kappa was 0.23 (indicating 
minimal inter-rater agreement), the intra-class correlation coefficient was excellent for the 
total score (ICC = 0.90; 95%CI: 0.92, 0.95; Table 5). With regard to individual items, kappa 
scores ranging from 0.30 to 0.85, indicating minimal to strong rater agreement (Table 5).
For the Independence Scale, clinician-rated significantly differed from self-report scores 
(t[481]=6.24; p<.0001; Table 2). With regard to the different HD stages, there were also 
group differences for the early-stage group (t[188]=5.96; p<.0001) and the late stage group 
(t[97]=4.35; p<.0001), but not the premanifest group (t[193]=0.74; p=.46; Table 3). There 
was 52% agreement between the clinician-rated and self-report Independence Scale scores. 
To achieve 75%, 90%, 95%, and 100% agreement, clinician-rated and self-report scores 
need to be within 1 point, 2, points, 2 points, and 6 points, respectively (Table 4). Intra-class 
correlations for the Independence Scale were acceptable (ICC = 0.88; 95% CI: 0.85, 0.90; 
Table 5).
Discussion
The purpose of this study was to examine the accuracy of self-report reported functioning in 
individuals with HD relative to associated clinician-ratings of the same construct. While 
self-report ratings and clinician-ratings were not a perfect match, self-ratings provided a 
reliable and valid alternative to clinician-ratings, especially when in person assessments are 
impractical or cost prohibitive for a particular study, or for observational or behavioral trials 
that are low risk. Our results indicated that self-reported ratings of functional capacity and 
functional ability internal consistency were good. Whereas clinician-reported ratings of the 
same constructs were excellent (and consistently higher than self-report ratings), the fact that 
the self-report ratings exceeded minimal acceptable criterion for internal consistency (i.e., 
> .70[62]) supports the reliability of the self-reported assessments. In addition, construct 
validity of self-reported functional ability and independence was supported by significant 
differences between those with premanifest, early-, and late-stage HD, such that those 
individuals with manifest HD (the early- and late-HD groups) reported less ability and 
independence than those with manifest HD, and those with late-stage HD reported less 
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ability and independence than those with early-HD. This pattern of findings was identical for 
the associated clinician rating scores for both functional ability and independence.
Although self-reported ratings significantly differed from clinician-ratings of the TFC (these 
differences were small, i.e., within .25 points of one another), and the agreement between 
individual items were not ideal, total scores agreed well on this measure. Self-report did not 
significantly differ from clinician-rated functional ability. When HD stage was considered, 
group differences were also not found between self- and clinician-reports for those with 
premanifest or late-stage HD; there were group differences on self- and clinician-report for 
those with early-HD, but this difference was small (less than 1 point). Furthermore, whereas 
agreement at the item-level was poor, FA total scores showed good agreement. Self-report 
ratings significantly differed from clinician ratings on the Independence Scale, but 
differences were small (within 0.5 of a point of one another). When HD stage was 
considered, self- and clinician-report differed for the two manifest groups but not the 
premanifest group; again differences were small (within 0.5 of a point for the early-group 
and 0.75 of a point for the late-HD group). Furthermore, item-level agreement was not 
optimal, but total score agreement was acceptable. Thus, while these findings indicate that 
the self-report TFC, FA and Independence do not perfectly match the associated clinician-
rated measures, the agreement is close enough to use with confidence in research studies that 
are behavioral or observational in design and are low risk, or where clinician-ratings are 
resource prohibitive or impractical.
Finally, Table 4 provides clinicians and researchers with recommendations for achieving 
specified levels of agreement. For example, if a clinician or researcher conducts a study 
utilizing self-reported TFC, they could be 75% confident that the self-reported score was 
within 2 points of the clinician-rated score, 90% confident that the clinician-rated score was 
within 4 points, 95% confident that it was within 5 points and 100% confident that it was 
within 7 points of clinician-rated TFC. On a scale where scores range from 0–13, one could 
rely solely on self-reported scores if 75% confidence was acceptable. If one wanted to 
achieve 90, 95, or 100% confidence, they would likely not rely on self-reported scores alone 
(as would likely be the case with medication based clinical trials). For FA, where scores 
range from 0 to 25, a clinician or researcher might be most comfortable using self-report if 
they required 90% agreement, in which case could be confident that the self-reported score 
was within 5 points of the clinician rated score which is ±20% of the score. Similarly, on 
Independence, where scores range from 0 to 100, a clinician or researcher might be most 
comfortable using self-report if they required 90%-95% agreement (in which case we could 
be confident that the self-reported score was within 20 points of the clinician rated score 
which is ±20% of the score). Thus, while these discrepancies may preclude the use of these 
self-report measures in pharmacological trials (where measurement error can be especially 
problematic[63, 64]), depending on the research question and the acceptable margin of error, 
Table 4 can be utilized to decide whether or not the benefits of using a self-reported score 
(efficiency, cost, etc), exceeds the margin of error that would be acceptable for any given 
research questions.
This study provides support for self-reported functional capacity, ability and independence, 
and helps determine when one might consider only using self-report and not clinician ratings 
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of these scales. The study has some limitations. First, cognitive impairment is common in 
HD,[28, 30, 65, 66] yet we did not administer any assessments to assess it directly, or 
estimate patient overall awareness in this study. Furthermore, we did not consider how other 
specific psychological or motivational factors such as depression, anxiety or apathy, may 
affect self-report or the relationship between self-report and clinician rating.
Regardless of these limitations, these findings provide important information for the clinical 
utility of the self-reported TFC, FA and Independence Scale. While the self-reported and 
clinician-rated scores are not identical, the self-reported versions demonstrated acceptable 
reliability. Any differences between scores were small, and there was generally good 
agreement for total scores supporting their clinical utility. Specifically, HD clinicians and 
researchers can consider administering the self-reported versions of these assessments when 
the study design permits, and obtaining clinician ratings if not feasible (either because of 
cost or availability of clinician time).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Statements
What is already known about the topic
Although clinician-rated assessments of functioning are often used as primary endpoints 
in Huntington disease research, there is a question of whether patient self-report may 
serve as acceptable alternatives in low risk observational or behavioral studies.
What the paper adds
This paper reports on the level of agreement between self-reported and clinician ratings 
of function in Huntington disease.
Implications for practice, theory or policy
While not an exact match for clinician-ratings of functioning, self-reported ratings of 
functioning may be appropriate for low risk observational or behavioral trials in 
Huntington disease when the costs associated with clinician ratings are not feasible.
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Table 1
Demographic characteristics of Individuals with HD, stratified by HD group
Variable Premanifest(N=195)
Early
(N=190)
Late
(N=101)
All
(N=486)
Age (years)*
M (SD) 42.9 (12.2) 52.0 (12.3) 55.5 (11.6) 49.0 (13.2)
Education (# of years)*
M (SD) 15.9 (2.9) 14.7 (2.8) 14.3 (2.7) 15.1 (2.9)
Gender (%)
Female 64.1 54.7 55.5 58.6
Male 35.9 45.3 44.5 42.4
Race (%)*
White 97.4 97.4 94.1 96.7
African American 0.0 1.1 5.9 1.7
More than One Race 1.5 0.0 0.0 0.6
American Indian/Alaskan Native 0.0 0.5 0.0 0.2
Other 0.0 1.0 0.0 0.6
Not Provided 0.5 0.0 0.0 0.2
Ethnicity (%)*
Not Hispanic or Latino 92.3 93.2 97.0 93.6
Hispanic or Latino 1.5 3.7 1.0 2.3
Not Provided 6.2 3.2 2.0 4.1
Marital Status (%)*
Single, Never Married 15.9 15.3 9.9 14.4
Married 67.7 54.0 66.3 62.0
Separated/Divorced 13.3 23.3 20.8 18.8
Widowed 0.0 3.2 3.0 1.9
Living with Partner 3.1 4.2 0.0 2.9
CAG Repeats*
M (SD) 42.1 (2.9) 43.0 (3.6) 44.5 (7.1) 42.8 (4.0)
Disease Burden (premanifest only)** -- -- --
Low Risk (%) 84.6 -- -- --
Intermediate Risk (%) 0.0 -- -- --
High Risk (%) 15.4 -- -- --
Time since diagnosis in years M(SD) (manifest only)* -- 3.5 (3.6) 6.3 (4.5) --
Note. Entries in the table represent percentage of participants unless otherwise specified;
*indicates significant group differences: age, (F[2, 483] = 45.3, p<.0001), early-HD participants were older than premanifest participants and late-
HD was older than early-HD; education (# of years), premanifest participants had more years of education than the other two groups (F[2, 481]= 
13.1; p<.0001); race (White, African American, More than One Race, American Indian/Alaskan Native, Other, Not Provided), late-HD had more 
African Americans than the other two groups, the premanifest group had more mixed race participants than the other groups (Fisher’s Exact p = .
0053) ; ethnicity (Not Hispanic/Latino, Hispanic/Latino, Not Provided) , more premanifest participant did not provide an ethnicity, late-HD had 
more Non-Hispanic/Latinos than the other two groups (Fisher’s Exact p=.0002); marital status (Single, Married, Separated/Divorced, Widowed, 
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Living with Partner), Premanifest participants were less likely to be separated/divorced or widowed than the other two groups (χ28 = 21.9, p=.
0051); and time since diagnosis (in years, manifest only), the late-HD group had approximately 3 more years since diagnosis than the early-HD 
group (t[135.5]= −4.7; p<.0001).
**
Disease burden was measured using CAP scores[54] to determine low, intermediate, or high risk of developing motor symptoms within the next 
5 years.
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Table 4
Total score differences required to achieve specified levels of agreement
75% 90% 95% 100%
Total Functional Capacity 2 Points 4 Points 5 Points 7 Points
Functional Assessment 2 Points 5 Points 7 Points 13 Points
Independence Scale 1 Point 2 Points 2 Points 6 Points
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Table 5
Agreement (Kappa and Intra-class correlation coefficients) for individual items and total scores for the 
UHDRS measures
Variable Kappa ICC (95% CI)
Total Functional Capacity (TFC)
Occupation 0.58 0.92 (.90, .93)
Chores 0.17 0.12 (−.05, .27)
ADL 0.34 0.47 (.37, .56)
Finances 0.47 0.86 (.84, .87)
Care Level 0.45 0.13 (−.08, .30)
TOTAL FUNCTIONAL CAPACITY TOTAL SCORE 0.14 0.89 (.87, .91)
Functional Assessment
Could the subject engage in gainful employment in his/her accustomed work? 0.74 0.85 (.81, .88)
Could the subject engage in any kind of gainful employment? 0.64 0.78 (.73, .83)
Could the subject engage in any kind of volunteer or non-gainful work? 0.53 0.69 (.62, .75)
Could the subject manage his/her finances (monthly) without any help? 0.63 0.78 (.72, .82)
Could the subject shop for groceries without help? 0.66 0.80 (.75, .84)
Could the subject handle money as a purchaser in a simple cash (store) transaction? 0.78 0.64 (.55, .71)
Could the subject supervise children without help? 0.63 0.78 (.72, .82)
Could the subject operate an automobile safely and independently? 0.85 0.92 (.90, .94)
Could the subject do his/her own housework without help? 0.62 0.76 (.70, .81)
Could the subject do his/her own laundry (wash/dry) without help? 0.79 0.88 (.85, .91)
Could the subject prepare his/her own meals without help? 0.61 0.76 (.70, .81)
Could the subject use the telephone without help? 0.30 0.46 (.33, .57)
Could the subject take his/her own medications without help? 0.62 0.77 (.71, .81)
Could the subject feed himself/herself without help? 0.52 0.69 (.61, .75)
Could the subject dress himself/herself without help? 0.66 0.80 (.75, .84)
Could the subject bathe himself/herself without help? 0.77 0.87 (.84, .90)
Could the subject use public transportation to get places without help? 0.68 0.81 (.76, .85)
Could the subject walk to places in his/her own neighborhood without help? 0.73 0.85 (.81, .88)
Could the subject walk without falling? 0.35 0.52 (.41, .62)
Could the subject walk without help? 0.59 0.75 (.68, .80)
Could the subject comb hair without help? 0.40 0.57 (.47, .66)
Could the subject transfer between chairs without help? 0.49 0.66 (.58, .73)
Could the subject get in and out of bed without help? 0.46 0.63 (.54, .70)
Could the subject use the toilet/commode without help? 0.85 0.92 (.90, .94)
Could the subject’s care still be provided at home? 0.55 0.71 (.64, .77)
FUNCTIONAL ASSESSMENT TOTAL SCORE 0.23 0.94 (.92, .95)
Independence Scale
INDEPENDENCE SCALE TOTAL SCORE - 0.88 (.85, .90)
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